Curis Lifesciences Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/to4llvi6ikvjw65dajy09o7b.pdf

Key Takeaways


Margin Transformation: Raw Materials & Registration

Jaimik Patel: "if I'll take the average, it will be 50% or 40% EBITDA margin for that sales only which we will going to achieve 10% of our total revenue in 27-28."

Business Model Reshaping: Exit Low Margin, Enter Exports

Jaimik Patel: "contract manufacturing for loan license and job per sales, we are going to close it, because there is no much margin, is it, in that, and there is no growth of company in that, to move forward with that. That we were doing is to just, survive the company."

Nigeria JV: Structure, Timeline & Revenue Path


Own-Brand Strategy: The Long Margin Bet

Jaimik Patel: "any pharmaceutical company, I don't know about the rich people, but if Pharma company, in Pharma people, they are recognized by their brand name only. Like, Troika is there, and then they are recognized by Dynapar brand name only. Ranbaxy was there, it was recognized by Volini Gel."

New Markets & Product Capabilities

Jaimik Patel: "without injectable, you cannot win any country."

Financial Position & Capex


Guidance & Commitments

CommitmentSpecificsTimeline
FY26 revenue growth20% YoY, may increase due to October fundraiseFY26 closing
FY26 EBITDA margin22% (up from 20.75% in 9M)FY26 closing
FY27 revenue growth20-25% YoYFY27
FY27 EBITDA marginAbove 12-15%FY27
Merchant export growth30-40% increase in contract manufacturing for merchant exportFY27
Nigeria revenue shareGrow from ~0.5% to 5-10% of total revenueFY27
Own-brand revenue share10% of total revenueFY28
Own-brand revenue share30% of total revenueFY29
Ghana audit and certificateAudit in March/April 2025; certificate within 2-3 months post-auditQ4 FY26 / Q1 FY27
Loan license / job work closureAlready stopped, less than 1% of salesEffective immediately
Injectable projectApply for 5,000 sqm land; one year stabilization post-license; six months to first ordersNo start date given

Key Metrics

MetricH1 FY26 / FY26
Revenue (H1 FY26)₹27.91 cr (30 Sep 2025)
Revenue (FY25)₹50.27 cr
Revenue (FY24)₹35.97 cr
Revenue (FY23)₹35.83 cr (36% domestic, 63.78% export)
Revenue (9M FY26)₹42 cr (by 31 Dec 2025)
FY26 revenue growth expectation20%, may increase further
FY27 revenue guidance₹55–60 cr
FY27 revenue growth expectation20–25%
EBITDA margin (FY23)9.80%
EBITDA margin (FY24)23.65%
EBITDA margin (FY25)21.40%
EBITDA margin (FY26 TTM)~20.75%
FY26 EBITDA margin expectation22%
FY27 EBITDA margin guidance22%
PAT margin (FY23)5.23%
PAT margin (FY24)14.13%
PAT margin (FY25)12.35%
PAT (FY25)₹6.1 cr
FY26 PAT growth expectation20–30% hike
FY27 PAT margin guidance15–17%
FY27 PBT margin guidance~19%
Net worth (FY23)0.95%
Net worth (FY24)5.97%
Net worth (FY25)16.52%
Own-brand direct export share<1% of total sales
Kenya share of sales20–30%
Nigeria share of sales (current)~0.5% of total revenue
Nigeria share of sales (FY27 expected)5–10% of total revenue
Contract manufacturing merchant export growth target (FY27)30–40% increase
Products developed>1,200, targeting 3,000
Annual product portfolio expansion20–30%
Inventory days (FY23)115
Inventory days (FY25)347
Payable days (Mar 2022)360
Payable days (current)112
IPO capex for factory upgrades₹2.61 cr
IPO working capital allocation~₹11 cr
Eurosun Nigeria standalone sales>₹10 cr
Injectables project capex estimate₹50–55 cr (incl. 2 years expense)
Injectables land requirement4,000–5,000 sq m